23 – 24 October, 2025 | Embassy of France, Washington, D. C., USA

A Multi-stakeholder Multi-specialty
NASH Trialists Think Tank

Metabolic, hepatology, nephrology & cardiovascular cross-talk

19 - 20 October, 2023

Georgetown University, Leavey Center, Washington, D. C.
Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health
Web Banner
Organized by
assets-05
In collaboration with
cvc
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health

19 – 20 October,
2023

Embassy of France
4101 Reservoir Road, NW – Washington, D.C. – 20007

Organized by
In collaboration

Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

assets-04
Organized by
assets-05
In collaboration with
cvc
assets-07
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Overview
MOSAIC - Global NASH/MASH Trialist Forum
brings together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks.
Special Announcement
It is with deep sadness that the MOSAIC team learned of the passing of Prof Stephen Harrison on 4/24/2024. Prof. Harrison was one of the key members in the MOSAIC project and will be greatly missed for his commitment to a multi organ and multi disciplinary approach to MASH/ MAFLD.
NASH/MASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH/MASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH/MASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
Who can participate?
Mosaic is an invitation only event for clinical trialists, investigators, methodologists, regulators, clinical research organizations, clinicians, epidemiologists, statisticians, payers, industry R&D experts, major journal editors, patients, patient trialists and patient advocacy representatives.
Why should you attend?
  • list icon
    Networking opportunities
  • list icon
    Think Tank focused Workshops
  • list icon
    Latest trials updates
  • list icon
    Patient participation
Faculty
Javed Butler (USA)
Javed Butler
USA
Veronica Miller
USA
Arun Sanyal
USA
chair-eclipse
Faiez Zannad
France
Topics
  • NASH/MASH – Cardiovascular intersections
  • Epidemiology, disease mechanisms
  • Non-invasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH/MASH trials
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
Topics